PDA

View Full Version : SNSS - Sunesis Pharmaceuticals Inc.



abkoqasav
08-06-2015,
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for hematologic and solid tumor cancers. Its primary product candidate is Voreloxin, an anticancer quinolone derivative (AQD) for the treatment of cancer in Phase 2 development stage. The company is conducting various clinical trials of Voreloxin, including a Phase 2 clinical trial, known as the REVEAL-1 trial, in previously untreated elderly patients with acute myeloid leukemia (AML); a Phase 1b/2 clinical trial combining Voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML; and a Phase 2 single agent clinical trial in advanced platinum-resistant ovarian cancer patients. Sunesis Pharmaceuticals has a license agreement with Dainippon Sumitomo Pharma Co., Ltd. for the development and marketing of Voreloxin. It was formerly known as Mosaic Pharmaceuticals, Inc. The company was founded in 1998 and is headquartered in South San Francisco, California.

Sunesis Pharmaceuticals Inc.
395 Oyster Point Boulevard
Suite 400
South San Francisco, CA 94080
United States - Map
Phone: 650-266-3500
Fax: 650-266-3505
Web Site: http://www.sunesis-pharma.com

abkekecifip
08-06-2015,
Recent News:
Sunesis Pharmaceuticals Initiates Phase II Clinical Trial of SNS-595 in Small Cell Lung Cancer

Insider Buy Posted Yesterday:
P 2006-03-17 2006-03-20
16:10:18 SUNESIS PHARMACEUTICALS INC SNSS WARBURG PINCUS EQUITY PARTNERS LP
WARBURG PINCUS & CO
WARBURG PINCUS LLC
Warburg Pincus Partners LLC 10% owner 805,153 $6.21 $5,000,000 3,626,875 Direct View

P 2005-09-27 2006-02-14
11:59:09 SUNESIS PHARMACEUTICALS INC SNSS BIOGEN IDEC INC
BIOGEN IDEC MA INC 10% owner 714,286 $7 $5,000,002 2,912,022 Indirect View

P 2005-09-30 2005-12-22
21:47:48 SUNESIS PHARMACEUTICALS INC SNSS MAYFIELD IX
MAYFIELD IX MANAGEMENT LLC
MAYFIELD ASSOCIATES FUND III L P
MAYFIELD VIII MANAGEMENT LLC
UNGER WILLIAM D
AUKEN WENDELL G VAN III
FONG KEVIN A
MYERS FRANK G JR
DALAL YOGEN K
HEIDRICH A GRANT III 10% owner 70,000 $7 $490,000 64,940 Direct
Indirect View
P 2005-09-30 2005-10-04
19:14:56 SUNESIS PHARMACEUTICALS INC SNSS MAYFIELD IX
MAYFIELD IX MANAGEMENT LLC
MAYFIELD ASSOCIATES FUND III L P
MAYFIELD VIII MANAGEMENT LLC
UNGER WILLIAM D
AUKEN WENDELL G VAN III
FONG KEVIN A
MYERS FRANK G JR
DALAL YOGEN K
HEIDRICH A GRANT III 10% owner 70,000 $7 $490,000 64,905 Direct
Indirect View

P 2005-09-30 2005-10-04
17:39:40 SUNESIS PHARMACEUTICALS INC SNSS LEFF JONATHAN S(X) Director
10% owner 445,000 $7 $3,115,000 1,379,127 Indirect View

P 2005-09-30 2005-09-30
18:12:28 SUNESIS PHARMACEUTICALS INC SNSS EVNIN ANTHONY B Director 135,000 $7 $945,000 649,955 Indirect View

P 2005-09-27 2005-09-29
15:58:30 SUNESIS PHARMACEUTICALS INC SNSS WARBURG PINCUS EQUITY PARTNERS LP
WARBURG PINCUS & CO
WARBURG PINCUS LLC
Warburg Pincus Partners LLC 10% owner 445,000 $7 $3,115,000 2,821,722 Direct View

ablktlnu73
08-07-2015,
Sunesis Pharmaceuticals Inc.
341 Oyster Point Boulevard
South San Francisco, CA 94080
Phone: 650-266-3500
Fax: 650-266-3505
Web Site: http://www.sunesis-pharma.com

Sunesis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for oncology, inflammatory diseases, and other unmet medical needs. Its fragment-based drug discovery approach, Tethering, combines with other drug discovery tools, such as structure-based design and medicinal chemistry to discover and develop novel therapeutics. The company’s pipeline includes SNS-595, a novel cell-cycle inhibitor for the treatment of cancer. Sunesis Pharmaceuticals was founded in 1998 and is headquartered in south San Francisco, California.

AbnormalReturns
08-09-2015,
add ANOTHER insider to the list:

P 2006-03-17 2006-03-22
21:56:55 SUNESIS PHARMACEUTICALS INC SNSS LEFF JONATHAN S(X) Director
10% owner 805,153 $6.21 $5,000,000 3,626,875 Indirect View

Abnormal Returns
08-09-2015,
Oh boy, news today loooks good on this one, and with the tiny float it should FLY

Sunesis Pharmaceuticals 4Q Rev $4.52M Vs $3.87M, +17%

SOUTH SAN FRANCISCO, Calif., March 24 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS - News), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics, today reported financial results for the quarter and fiscal year ended December 31, 2005. Total revenues for the fourth quarter were $4.5 million, with a net loss of $5.3 million. Total revenues for 2005 were $16.5 million, with a net loss of $27.5 million. As of December 31, 2005, cash, cash equivalents and marketable securities totaled $48.3 million and debt totaled $2.4 million.

admin
08-10-2015,
Sunesis Pharma reports positive initial results from Phase 2 small cell lung cancer trial with SNS-595 (SNSS) 4.66 : Co announces that the co will advance the small-cell lung cancer trial in treatment-sensitive patients to Stage 2. The co reported initial results from the first stages of two Phase 2 clinical trials of SNS-595, a novel cell-cycle inhibitor, in first-line relapsed/refractory small cell and non-small cell lung cancers. Anti-tumor activity was observed, including evidence of stable disease, minor responses and partial responses reported in one arm of the small cell lung cancer study, and minor and mixed responses and stable disease in the non-small cell lung cancer trial.